Clinicopathological prognostic indicators in 107 patients with diffuse large B-cell lymphoma transformed from follicular lymphoma

Cancer Science

Volumn 104, Issue 7, 2013, Pages 952-957

  Maeshima, Akiko M ^a   Taniguchi, Hirokazu ^a   Fukuhara, Suguru ^a   Maruyama, Dai ^a   Kim, Sung Won ^a   Watanabe, Takashi ^a   Kobayashi, Yukio ^a   Tobinai, Kensei ^a   Tsuda, Hitoshi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; INTERFERON REGULATORY FACTOR 4; KI 67 ANTIGEN; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

CELL TRANSFORMATION, NEOPLASTIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

EID: 84880747381     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12158     Document Type: Article

References (32)

1. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909-18.
2. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphoma. N Engl J Med 1984; 311: 1471-5.
3. Gallagher CJ, Gregory WM, Jones AE et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986; 4: 1470-80.
4. Harris NL, Ferry JA. Follicular lymphoma. In: Knowles DM, ed. Neoplastic Hematopathology, 2nd edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2001; 823-53.
5. Alsabeh R, Medeiros LJ, Glackin C et al. Transformation of follicular lymphoma into CD30-large cell lymphoma with anaplastic cytologic features. Am J Surg Pathol 1997; 21: 528-36.
6. Yano T, Jaffe ES, Longo DJ et al. MYC rearrangements in histologically progressed follicular lymphomas. Blood 1992; 80: 758-67.
7. de Jong D, Voetdujk B, Bavestock G et al. Activation of the c-myc oncogene in a precursor B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. N Engl J Med 1998; 318: 1373-8.
8. Brauninger A, Hansmann ML, Strickler JG et al. Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med 1999; 340: 1239-47.
9. Marafioti T, Hummel M, Anagnostopoulos I et al. Classical Hodgkin's disease and follicular lymphoma originating from the same germinal center B cell. J Clin Oncol 1999; 17: 3804-9.
10. Ghesquières H, Berger F, Felman P et al. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. J Clin Oncol 2006; 24: 5234-41.
11. Lossos IS, Alizadeh AA, Diehn M et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci USA 2002; 99: 8886-91.
12. Sander CA, Yano T, Clark HM et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993; 82: 1994-2004.
13. Davies AJ, Rosenwald A, Wright G et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol 2007; 136: 286-93.
14. Pinyol M, Cobo F, Bea S et al. p16 (INF4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998; 91: 2977-84.
15. Elenitoba-Johnson KS, Gascoyne RD, Lim MS et al. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 1998; 91: 4677-85.
16. Hans CP, Weisenburger DD, Vose JM et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 2003; 101: 2363-7.
17. Maeshima AM, Omatsu M, Nomoto J et al. Diffuse large B-cell lymphoma after transformation from low-grade follicular lymphoma: morphological, immunohistochemical, and FISH analyses. Cancer Sci 2008; 99: 1760-8.
18. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
19. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 1937-47.
20. Hans SP, Weisenburger DD, Greiner TC et al. Conformation of molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82.
21. Godon A, Moreau A, Talmant P et al. Is t(14;18)(q32;q21) a constant finding in follicular lymphoma? An interphase FISH study on 63 patients Leukemia 2003; 17: 255-9.
22. Biagi JJ, Suymour JF. Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood 2002; 99: 4265-75.
23. Sekiguchi N, Kobayashi Y, Yokota Y et al. Follicular lymphoma subgrouping by fluorescence in situ hybridization analysis. Cancer Sci 2005; 96: 77-82.
24. Swerdlow SH, Campo E, Harris NL et al. World health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008.
25. Miller TP, Grogan TM, Dahlberg S et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 1994; 83: 1460-6.
26. Maeshima AM, Taniguchi H, Fukuhara S et al. Bcl-2, Bcl-6, and IPI are prognostic indicators in patients with DLBCL treated with rituximab-containing chemotherapy. Cancer Sci 2012; 103: 1898-904.
27. Nunez G, London L, Hockenbery D et al. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 1990; 144: 3602-10.
28. Gascoyne RD, Adomat SA, Krajewski S et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 244-51.
29. Hermine O, Haioun C, Lepage E et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groups d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996; 87: 265-72.
30. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
31. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 1937-47.
32. Colomo L, Lopez-Guillermo A, Perales M et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78-84.